Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zolucatetide (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin; Tipiracil/trifluridine
  • Indications Colorectal cancer; Craniopharyngioma; Familial adenomatous polyposis; Fibroma; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Parabilis Medicines

Most Recent Events

  • 13 Aug 2026 According to Parabilis Medicines media release, company expects to share clinical data from additional patients in the first half of 2027 for Adamantinomatous craniopharyngioma (ACP).
  • 13 Aug 2026 According to Parabilis Medicines media release, company expects to initiate enrollment in a dedicated clinical cohort evaluating zolucatetide in patients with FAP during the second half of 2026 and disclosing additional FAP data in the first quarter of 2027.
  • 23 Jul 2026 The protocol has been amended to add Familial adenomatous polyposis (FAP) indication arm, number of arms changed form 18 to 19.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top